Amarin Stock Price, News & Analysis (NASDAQ:AMRN)

$3.33 0.08 (2.46 %)
(As of 12/12/2017 12:55 PM ET)
Previous Close$3.25
Today's Range$3.23 - $3.34
52-Week Range$2.81 - $4.47
Volume1.61 million shs
Average Volume1.72 million shs
Market Capitalization$880.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.66

About Amarin (NASDAQ:AMRN)

Amarin logoAmarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Debt-to-Equity Ratio-1.48%
Current Ratio1.63%
Quick Ratio1.32%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$130.08 million
Price / Sales6.93
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-27.75

Profitability

Trailing EPS($0.27)
Net Income$-86,350,000.00
Net Margins-43.90%
Return on EquityN/A
Return on Assets-35.67%

Miscellaneous

Employees215
Outstanding Shares270,880,000

Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. The biopharmaceutical company earned $47.10 million during the quarter, compared to the consensus estimate of $45.85 million. The business's revenue for the quarter was up 45.4% on a year-over-year basis. During the same period last year, the firm earned ($0.08) EPS. View Amarin's Earnings History.

When will Amarin make its next earnings announcement?

Amarin is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Amarin.

Where is Amarin's stock going? Where will Amarin's stock price be in 2017?

3 analysts have issued twelve-month price targets for Amarin's shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate Amarin's share price to reach $9.00 in the next year. View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:

  • 1. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (11/3/2017)
  • 2. Cantor Fitzgerald analysts commented, "At ESC, Novartis released data from its Phase 3 CANTOS study for ACZ885." (8/29/2017)

Who are some of Amarin's key competitors?

Who are Amarin's key executives?

Amarin's management team includes the folowing people:

  • Lars G. Ekman M.D., Ph.D., Independent Chairman of the Board (Age 67)
  • John F. Thero CPA, President, Chief Executive Officer, Assistant Secretary, Director (Age 56)
  • Michael Wayne Kalb CPA, Chief Financial Officer, Senior Vice President (Age 45)
  • Stephen B. Ketchum Ph.D., President - Research and Development, Senior Vice President, Chief Scientific Officer (Age 50)
  • Joseph T. Kennedy J.D., Senior Vice President, Chief Compliance Officer, General Counsel, Secretary (Age 47)
  • Aaron D. Berg, Senior Vice President - Marketing and Sales (Age 53)
  • Michael J. Farrell, Vice President - Finance (principal accounting officer and principal financial officer) (Age 37)
  • Craig B. Granowitz M.D., Ph.D., Chief Medical Officer
  • Mark W. Salyer, Chief Commercial Officer
  • Joseph S. Zakrzewski, Director (Age 54)

Who owns Amarin stock?

Amarin's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Alkeon Capital Management LLC (0.83%), University of Notre Dame DU Lac (0.30%), JPMorgan Chase & Co. (0.04%), Neuberger Berman Group LLC (0.04%), GSA Capital Partners LLP (0.03%) and TD Asset Management Inc. (0.03%). Company insiders that own Amarin stock include John F Thero, Joseph T Kennedy and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Who sold Amarin stock? Who is selling Amarin stock?

Amarin's stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, JPMorgan Chase & Co., Dynamic Technology Lab Private Ltd and Sterling Capital Management LLC. Company insiders that have sold Amarin company stock in the last year include Joseph T Kennedy and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Who bought Amarin stock? Who is buying Amarin stock?

Amarin's stock was bought by a variety of institutional investors in the last quarter, including Alkeon Capital Management LLC, University of Notre Dame DU Lac, Neuberger Berman Group LLC, TD Asset Management Inc., Stevens Capital Management LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Amarin.

How do I buy Amarin stock?

Shares of Amarin can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of Amarin stock can currently be purchased for approximately $3.33.

How big of a company is Amarin?

Amarin has a market capitalization of $880.36 million and generates $130.08 million in revenue each year. The biopharmaceutical company earns $-86,350,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Amarin employs 215 workers across the globe.

How can I contact Amarin?

Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (AMRN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  403 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  625
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amarin (NASDAQ:AMRN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.00$8.00$6.25
Price Target Upside: 161.44% upside135.29% upside153.97% upside110.44% upside

Amarin (NASDAQ:AMRN) Consensus Price Target History

Price Target History for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ:AMRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/6/2017Cantor FitzgeraldSet Price TargetBuy$10.00HighView Rating Details
11/2/2017HC WainwrightReiterated RatingBuy$10.00N/AView Rating Details
10/11/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/19/2016CitigroupInitiated CoverageBuy$5.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Amarin (NASDAQ:AMRN) Earnings History and Estimates Chart

Earnings by Quarter for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ AMRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018        
11/1/2017Q3 2017($0.05)($0.04)$45.85 million$47.10 millionViewN/AView Earnings Details
8/2/20176/30/2017($0.06)($0.05)$40.35 million$44.95 millionViewListenView Earnings Details
5/4/20173/31/2017($0.07)($0.08)$37.85 million$34.60 millionViewListenView Earnings Details
2/28/201712/31/2016($0.09)($0.05)$36.13 million$38.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.08)$32.03 million$32.40 millionViewN/AView Earnings Details
8/4/2016Q216($0.13)($0.07)$29.97 million$32.82 millionViewN/AView Earnings Details
5/5/2016Q116($0.11)($0.14)$26.77 million$25.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.08)($0.12)$23.62 million$26.40 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.18)$21.93 million$21.30 millionViewN/AView Earnings Details
8/6/2015Q2($0.12)($0.15)$19.10 million$17.70 millionViewN/AView Earnings Details
5/8/2015Q115($0.11)($0.18)$21.86 million$15.60 millionViewN/AView Earnings Details
3/3/2015Q414($0.13)($0.11)$17.40 million$16.50 millionViewN/AView Earnings Details
11/6/2014Q314($0.14)($0.18)$14.87 million$14.15 millionViewN/AView Earnings Details
8/7/2014Q214($0.15)($0.14)$12.86 million$12.60 millionViewN/AView Earnings Details
5/9/2014Q114($0.18)($0.17)$11.65 million$11.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.23)($0.26)$11.17 million$10.10 millionViewN/AView Earnings Details
11/7/2013($0.32)($0.25)$10.25 million$8.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.38)($0.26)$5.50 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.39)($0.41)$5.21 million$2.34 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.28)($0.28)ViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Amarin (NASDAQ:AMRN) Earnings Estimates

2017 EPS Consensus Estimate: ($0.23)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.07)($0.06)($0.07)
Q2 20172($0.06)($0.06)($0.06)
Q3 20172($0.05)($0.05)($0.05)
Q4 20172($0.06)($0.04)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Amarin (NASDAQ:AMRN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Amarin (NASDAQ AMRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.72%
Institutional Ownership Percentage: 40.17%
Insider Trades by Quarter for Amarin (NASDAQ:AMRN)
Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ AMRN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2017John F TheroInsiderBuy10,000$3.24$32,400.00View SEC Filing  
10/5/2017Steven B KetchumInsiderSell63,479$3.48$220,906.92View SEC Filing  
7/3/2017Joseph T. KennedyGeneral CounselSell307,911$4.00$1,231,644.00View SEC Filing  
2/1/2016John F TheroCEOBuy25,000$1.37$34,250.00View SEC Filing  
8/11/2015John F TheroCEOBuy20,000$2.35$47,000.00View SEC Filing  
11/12/2014John F TheroInsiderBuy50,000$0.83$41,500.00View SEC Filing  
11/11/2014Michael James FarrellInsiderBuy5,500$0.84$4,620.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amarin (NASDAQ AMRN) News Headlines

Source:
DateHeadline
Amarin (AMRN) PT Set at $10.00 by Cantor FitzgeraldAmarin (AMRN) PT Set at $10.00 by Cantor Fitzgerald
www.americanbankingnews.com - December 6 at 6:26 PM
Amarin Co. plc (AMRN) Expected to Post Quarterly Sales of $50.30 MillionAmarin Co. plc (AMRN) Expected to Post Quarterly Sales of $50.30 Million
www.americanbankingnews.com - December 6 at 6:22 PM
Amarin Co. plc (AMRN) Insider Acquires $32,400.00 in StockAmarin Co. plc (AMRN) Insider Acquires $32,400.00 in Stock
www.americanbankingnews.com - December 4 at 11:42 AM
Zacks: Brokerages Anticipate Amarin Co. plc (AMRN) Will Announce Earnings of -$0.04 Per ShareZacks: Brokerages Anticipate Amarin Co. plc (AMRN) Will Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - December 4 at 1:32 AM
ETFs with exposure to Amarin Corp. Plc : November 28, 2017ETFs with exposure to Amarin Corp. Plc : November 28, 2017
finance.yahoo.com - November 28 at 3:07 PM
Amarin Co. plc (AMRN) Given Average Rating of "Hold" by BrokeragesAmarin Co. plc (AMRN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:06 AM
Comparing Amarin Corporation PLC (AMRN) and Imprimis Pharmaceuticals (IMMY)Comparing Amarin Corporation PLC (AMRN) and Imprimis Pharmaceuticals (IMMY)
www.americanbankingnews.com - November 23 at 5:46 PM
Amarin Corporation PLC (AMRN) versus Its Competitors Head-To-Head ReviewAmarin Corporation PLC (AMRN) versus Its Competitors Head-To-Head Review
www.americanbankingnews.com - November 22 at 11:31 AM
Zacks: Analysts Anticipate Amarin Corporation PLC (AMRN) Will Post Quarterly Sales of $50.30 MillionZacks: Analysts Anticipate Amarin Corporation PLC (AMRN) Will Post Quarterly Sales of $50.30 Million
www.americanbankingnews.com - November 17 at 4:52 AM
ValuEngine Downgrades Amarin Corporation PLC (AMRN) to SellValuEngine Downgrades Amarin Corporation PLC (AMRN) to Sell
www.americanbankingnews.com - November 17 at 12:56 AM
Amarin: A Likely Runner In 2018 - Seeking AlphaAmarin: A Likely Runner In 2018 - Seeking Alpha
seekingalpha.com - November 16 at 4:04 PM
Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular RiskReal World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk
finance.yahoo.com - November 14 at 9:24 PM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney DiseaseVascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease
finance.yahoo.com - November 14 at 2:39 AM
Cantor Fitzgerald Analysts Give Amarin Corporation PLC (AMRN) a $10.00 Price TargetCantor Fitzgerald Analysts Give Amarin Corporation PLC (AMRN) a $10.00 Price Target
www.americanbankingnews.com - November 13 at 4:30 PM
Amarin Corporation PLC (AMRN) Expected to Post Q4 2017 Earnings of ($0.06) Per ShareAmarin Corporation PLC (AMRN) Expected to Post Q4 2017 Earnings of ($0.06) Per Share
www.americanbankingnews.com - November 8 at 4:34 PM
Drug Makers Stock Performance Review -- Amarin, Endo, Ionis Pharma, and Teva Pharma - PR Newswire (press release)Drug Makers Stock Performance Review -- Amarin, Endo, Ionis Pharma, and Teva Pharma - PR Newswire (press release)
www.prnewswire.com - November 8 at 3:27 PM
Amarin to Present at the Jefferies London Healthcare Conference - GlobeNewswire (press release)Amarin to Present at the Jefferies London Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 8 at 3:27 PM
Amarin Corporation PLC Expected to Post FY2017 Earnings of ($0.22) Per Share (AMRN)Amarin Corporation PLC Expected to Post FY2017 Earnings of ($0.22) Per Share (AMRN)
www.americanbankingnews.com - November 8 at 12:30 PM
ETFs with exposure to Amarin Corp. Plc : November 6, 2017ETFs with exposure to Amarin Corp. Plc : November 6, 2017
finance.yahoo.com - November 6 at 4:39 PM
Jefferies Group Research Analysts Cut Earnings Estimates for Amarin Corporation PLC (AMRN)Jefferies Group Research Analysts Cut Earnings Estimates for Amarin Corporation PLC (AMRN)
www.americanbankingnews.com - November 6 at 1:58 PM
Brokers Issue Forecasts for Amarin Corporation PLCs Q4 2017 Earnings (AMRN)Brokers Issue Forecasts for Amarin Corporation PLC's Q4 2017 Earnings (AMRN)
www.americanbankingnews.com - November 6 at 9:49 AM
Amarin Corporation PLC (AMRN) Downgraded by Zacks Investment ResearchAmarin Corporation PLC (AMRN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 4 at 6:40 PM
Amarin Corporation PLC (AMRN) Upgraded at ValuEngineAmarin Corporation PLC (AMRN) Upgraded at ValuEngine
www.americanbankingnews.com - November 4 at 4:43 PM
Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 3:56 PM
Equities Analysts Issue Forecasts for Amarin Corporation PLCs FY2020 Earnings (AMRN)Equities Analysts Issue Forecasts for Amarin Corporation PLC's FY2020 Earnings (AMRN)
www.americanbankingnews.com - November 2 at 5:34 PM
Amarin Corporation PLC (AMRN) Given Average Rating of "Buy" by BrokeragesAmarin Corporation PLC (AMRN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 2 at 2:14 AM
Edited Transcript of AMRN earnings conference call or presentation 1-Nov-17 12:00pm GMTEdited Transcript of AMRN earnings conference call or presentation 1-Nov-17 12:00pm GMT
finance.yahoo.com - November 1 at 9:37 PM
Amarin reports 3Q lossAmarin reports 3Q loss
finance.yahoo.com - November 1 at 4:24 PM
Company Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Announces 3Q:17 Financial Results and Provides Update on OperationsCompany Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Announces 3Q:17 Financial Results and Provides Update on Operations
finance.yahoo.com - November 1 at 4:24 PM
Amarin Corporation PLC (AMRN) Issues  Earnings Results, Beats Expectations By $0.01 EPSAmarin Corporation PLC (AMRN) Issues Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 1 at 1:36 PM
Amarin Corporation PLC (AMRN) Expected to Announce Quarterly Sales of $46.00 MillionAmarin Corporation PLC (AMRN) Expected to Announce Quarterly Sales of $46.00 Million
www.americanbankingnews.com - October 28 at 11:04 AM
Amarin Corporation PLC (AMRN) Scheduled to Post Earnings on WednesdayAmarin Corporation PLC (AMRN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 26 at 1:18 PM
Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 - GlobeNewswire (press release)Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 - GlobeNewswire (press release)
globenewswire.com - October 26 at 10:46 AM
-$0.05 EPS Expected for Amarin Corporation PLC (AMRN) This Quarter-$0.05 EPS Expected for Amarin Corporation PLC (AMRN) This Quarter
www.americanbankingnews.com - October 26 at 3:08 AM
Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 - NasdaqAmarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 - Nasdaq
www.nasdaq.com - October 25 at 4:55 PM
Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017
finance.yahoo.com - October 25 at 4:55 PM
ETFs with exposure to Amarin Corp. Plc : October 23, 2017ETFs with exposure to Amarin Corp. Plc : October 23, 2017
finance.yahoo.com - October 23 at 4:56 PM
Amarin Corporation PLC (AMRN) Given Buy Rating at Jefferies Group LLCAmarin Corporation PLC (AMRN) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - October 11 at 9:42 PM
Jefferies Group Weighs in on Amarin Corporation PLCs Q3 2017 Earnings (AMRN)Jefferies Group Weighs in on Amarin Corporation PLC's Q3 2017 Earnings (AMRN)
www.americanbankingnews.com - October 11 at 7:37 AM
ETFs with exposure to Amarin Corp. Plc : October 10, 2017ETFs with exposure to Amarin Corp. Plc : October 10, 2017
finance.yahoo.com - October 10 at 5:15 PM
 Analysts Expect Amarin Corporation PLC (AMRN) Will Announce Quarterly Sales of $45.10 Million Analysts Expect Amarin Corporation PLC (AMRN) Will Announce Quarterly Sales of $45.10 Million
www.americanbankingnews.com - October 9 at 9:22 AM
Amarin Corporation PLC (AMRN) Insider Steven B. Ketchum Sells 63,479 SharesAmarin Corporation PLC (AMRN) Insider Steven B. Ketchum Sells 63,479 Shares
www.americanbankingnews.com - October 6 at 10:34 PM
ETFs with exposure to Amarin Corp. Plc : September 28, 2017ETFs with exposure to Amarin Corp. Plc : September 28, 2017
finance.yahoo.com - October 2 at 3:39 PM
FY2018 EPS Estimates for Amarin Corporation PLC (AMRN) Boosted by AnalystFY2018 EPS Estimates for Amarin Corporation PLC (AMRN) Boosted by Analyst
www.americanbankingnews.com - September 28 at 2:28 PM
Amarin Reaches A Canadian Deal - Seeking AlphaAmarin Reaches A Canadian Deal - Seeking Alpha
seekingalpha.com - September 27 at 8:05 PM
Amarin Corporation PLCs (AMRN) "Buy" Rating Reiterated at Cantor FitzgeraldAmarin Corporation PLC's (AMRN) "Buy" Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - September 27 at 6:10 PM
SunTrust Banks Research Analysts Boost Earnings Estimates for Amarin Corporation PLC (AMRN)SunTrust Banks Research Analysts Boost Earnings Estimates for Amarin Corporation PLC (AMRN)
www.americanbankingnews.com - September 27 at 4:56 PM
Comparing Neurocrine Biosciences (NBIX) and Amarin Corporation PLC (AMRN)Comparing Neurocrine Biosciences (NBIX) and Amarin Corporation PLC (AMRN)
www.americanbankingnews.com - September 22 at 9:02 AM
Amarin to Present at Cantor Global Healthcare Conference - GlobeNewswire (press release)Amarin to Present at Cantor Global Healthcare Conference - GlobeNewswire (press release)
www.globenewswire.com - September 20 at 9:03 PM
Amarin to Present at Cantor Global Healthcare ConferenceAmarin to Present at Cantor Global Healthcare Conference
feeds.benzinga.com - September 20 at 5:16 PM

SEC Filings

Amarin (NASDAQ:AMRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amarin (NASDAQ:AMRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amarin (NASDAQ AMRN) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.